What does Rakesh Jhunjhunwala see in Jubilant Life Sciences?
Within a year, the investing legend has doubled down on his latest pharma bet
Himanshu Kakkar - May 23, 2020
Swipe right yet?
Dating apps are getting a lot of love, but they have a long way to go before making any profit
Shruti Venkatesh - March 06, 2020
Let’s talk payback
Paytm changed the way Indians spend but its business model could just face its biggest challenge yet
Kripa Mahalingam - November 28, 2019
Everything to everyone
In this edition, you will learn the perils of taking too many risks and of taking too few
N Mahalakshmi - November 19, 2019
Bane of intelligence
Author David Robson plays explains how high IQ, education and expertise could fuel stupidity
August 30, 2019
New growth model
Indian pharma majors are facing their toughest year yet in the US, with regulatory clampdown, hostile political environment and falling prices. Is reinvention the answer to their woes?
Kripa Mahalingam - July 26, 2019
Tricky Transition
Generic Indian pharma players are changing their formula to focus on high-margin complex generics and specialty drugs
N Mahalakshmi - July 16, 2019
Easy money
Waltz in and out of stores while your phone makes the payments, or have your loan okayed in a few hours. It’s never been easier to borrow or spend
Kripa Mahalingam - June 26, 2019
Growth Inhibitor
In Ankleshwar, feisty MSMEs that survived the Chinese onslaught say that the fight against red tapism is harder
Krishna Gopalan - January 25, 2019
Injecting Growth
By focusing on its strength in manufacturing lyophilized injectables, Gufic Biosciences has made a strong comeback and wants to aggressively push into the EU market next
Jash Kriplani - April 16, 2018
